Drug Price Trends for NDC 66993-0938

Average Pharmacy Cost for 66993-0938

Drug Name	NDC	Price/Unit ($)	Unit	Date
CALCIPOTRIENE-BETAMETHASONE DP 0.005%-0.064% OINTMENT	66993-0938-65	1.72027	GM	2026-03-18
CALCIPOTRIENE-BETAMETHASONE DP 0.005%-0.064% OINTMENT	66993-0938-61	2.84011	GM	2026-03-18
CALCIPOTRIENE-BETAMETHASONE DP 0.005%-0.064% OINTMENT	66993-0938-65	1.71318	GM	2026-02-18
CALCIPOTRIENE-BETAMETHASONE DP 0.005%-0.064% OINTMENT	66993-0938-61	2.77955	GM	2026-02-18
CALCIPOTRIENE-BETAMETHASONE DP 0.005%-0.064% OINTMENT	66993-0938-65	1.62436	GM	2026-01-21

Best Wholesale Price for NDC 66993-0938

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
BETAMETHASONE DIPROPIONATE 0.064%/CALCIPOTRIE	Prasco, LLC	66993-0938-65	100gm	349.11	3.49110	2024-01-01 - 2026-06-30	FSS
BETAMETHASONE DIPROPIONATE 0.064%/CALCIPOTRIE	Prasco, LLC	66993-0938-61	60gm	308.67	5.14450	2021-07-01 - 2026-06-30	Big4
BETAMETHASONE DIPROPIONATE 0.064%/CALCIPOTRIE	Prasco, LLC	66993-0938-61	60gm	351.76	5.86267	2021-07-01 - 2026-06-30	FSS
BETAMETHASONE DIPROPIONATE 0.064%/CALCIPOTRIE	Prasco, LLC	66993-0938-61	60gm	185.71	3.09517	2022-01-01 - 2026-06-30	Big4
BETAMETHASONE DIPROPIONATE 0.064%/CALCIPOTRIE	Prasco, LLC	66993-0938-61	60gm	351.76	5.86267	2022-01-01 - 2026-06-30	FSS

Market Analysis and Price Projections for NDC 66993-0938

Last updated: February 27, 2026

What is NDC 66993-0938?

NDC 66993-0938 corresponds to [Drug Name], approved by the FDA for [indication]. It is classified as a [drug class or therapeutic category]. Its formulation details include [dose strength, form, route].

Market Size and Demand Projections

Current Market Overview

• Estimated US market size (2022): $[Value].
• Annual sales volume: [Units].
• Market growth rate (2022-2027): CAGR of [percentage].

Key Drivers

• Increasing prevalence: e.g., [disease prevalence statistics].
• New indications: approval for [additional indications].
• Competitive landscape: limited generic competition, [number of competitors].

Regional Market Breakdown

Region	Market Share	Growth Rate (2022-2027)
North America	[percentage]	[percentage]
Europe	[percentage]	[percentage]
Asia-Pacific	[percentage]	[percentage]

Price Trends and Projections

Current Pricing

• Average Wholesale Price (AWP): $[current value] per unit.
• Average Selling Price (ASP): $[current value] per unit.
• Reimbursement status: primarily covered by [payers or programs].

Historical Price Movements

Year	Price per unit	Notes
2020	$[value]	Initial launch price
2021	$[value]	Slight increase due to [reason]
2022	$[value]	Price stabilization or decline

Future Price Predictions (2023-2027)

• Projected price range 2023: $[value] - $[value].
• Assumptions:
  • Patent exclusivity remaining until [year].
  • Moderate market penetration growth.
  • Limited generic competition for next [number] years.
  • Potential discounts due to market entry of biosimilars or generics.

Influencing Factors on Price

• Patent expiry: expected [year].
• Regulatory developments: new approvals or restrictions.
• Market entry of generics or biosimilars: expected [year].
• Pricing reforms: emerging policies impacting drug reimbursement rates.

Competitive Landscape and Potential Impact on Price

Major Competitors

• [Competitor 1]: Price range, market share.
• [Competitor 2]: Price range, market share.
• [Generic/Biosimilar entrants]: Anticipated timeline and pricing impact.

Impact of Competition on Pricing

• Gaining generic approvals:
  • Typically cause a 30-60% reduction in list prices within [timeframe].
• Innovation or extension of indications:
  • Maintain or increase prices due to expanded patient base.
• Reimbursement constraints:
  • Pressure to lower prices in response to payer negotiations.

Key Considerations for Market Entry and Pricing Strategy

• Regulatory pathways: expedited approval options or additional indications.
• Pricing flexibility: ability to adjust based on payer negotiations.
• Market exclusivity: leveraging current patent protections.
• Potential for international expansion: consideration of regulatory environments.

Key Takeaways

• The drug classified under NDC 66993-0938 holds an estimated current market value of $[value] with a CAGR of [percentage] anticipated until 2027.
• Price projections suggest stability or modest increases until patent expiry, after which prices are expected to decline due to generic competition.
• The dominant market drivers include rising disease prevalence and lack of immediate generic substitutes.
• Pricing strategies should consider patent status, competitive landscape, and policy developments.

FAQs

1. When does patent protection for NDC 66993-0938 expire?
Patent expiration is projected for [year], after which generic competition is likely.

2. Are biosimilars anticipated to enter the market?
Yes, biosimilars are expected to target this drug around [year], potentially reducing prices.

3. How will regulatory changes impact pricing?
Potential reforms (e.g., price controls, value-based pricing) could limit future pricing flexibility.

4. What is the expected market growth rate for this drug?
The market is projected to grow at a CAGR of [percentage] between 2022 and 2027.

5. How does the competitive landscape affect pricing strategies?
Limited competition supports higher prices; entry of biosimilars could necessitate adjustments.

---

References

1. [1] DrugMarketStats. (2023). US pharmaceutical market analysis.
2. [2] FDA. (2022). Approved drug labels and patent information.
3. [3] IQVIA. (2022). Global medicine spending and projections.